ALNY FY 2023 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$43B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1.8B+76.2% YoY

Gross Profit

$1.5B83.0% margin

Operating Income

-$282M-15.4% margin

Net Income

-$440M-24.1% margin

EPS (Diluted)

$-3.52

Cash Flow

Operating Cash Flow

$104M

Free Cash Flow

$42M

Stock-Based Comp.

$222M

Balance Sheet

Total Assets

$3.8B

Total Liabilities

$4.1B

Stockholders' Equity

-$221M

Cash & Equivalents

$813M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.8B	$1.0B	+76.2%
Gross Profit	$1.5B	$869M	+74.8%
Operating Income	-$282M	-$785M	+64.1%
Net Income	-$440M	-$1.1B	+61.1%